Determination of Deficiency. Upon receipt of a Deficiency Notice, Patheon will have [**] days to advise Client by notice in writing that it disagrees with the contents of the Deficiency Notice. If Client and Patheon fail to agree within [**] days after Patheon's notice to Client as to whether any Products identified in the Deficiency Notice deviate from the Specifications, cGMPs, or Applicable Laws, then the parties will mutually select an independent laboratory to evaluate if the Products deviate from the Specifications, cGMPs, or Applicable Laws. This evaluation will be binding on the parties. If the evaluation certifies that any Products deviate from the Specifications, cGMPs, or Applicable Laws, Client may reject those Products in the manner contemplated in this Section 6.1 and Patheon will be responsible for the cost of the evaluation. If the evaluation does not so certify for any of the Products, then Client will be deemed to have accepted delivery of the Products and Client will be responsible for the cost of the evaluation.
Appears in 2 contracts
Samples: Product Agreement (La Jolla Pharmaceutical Co), Product Agreement (Tetraphase Pharmaceuticals Inc)
Determination of Deficiency. Upon receipt of a Deficiency Notice, Patheon will have [**] ten days to advise Client by notice in writing that it disagrees with of its position relative to the contents of the Deficiency Notice. If Client and Patheon fail to agree within [**] ten days after Patheon's notice to Client as to whether any Products identified in the Deficiency Notice deviate from the Specifications, cGMPs, or Applicable Laws, then the parties will mutually select an independent laboratory to evaluate if the Products deviate from the Specifications, cGMPs, or Applicable Laws. This evaluation will be binding on the parties. If the evaluation certifies that any Products deviate from the Specifications, cGMPs, or Applicable Laws, then such Product shall be deemed rejected by Client may reject those Products in the manner contemplated in this Section 6.1 and Patheon will be responsible for the cost of the evaluation. If the evaluation does not so certify for any of the Products, then Client will be deemed to have accepted delivery of the Products on the [***] after delivery (or, in the case of any defects not reasonably susceptible to discovery upon receipt of the Product, on the [***] after discovery thereof by Client, but not after the expiration date of the Product) and Client will be responsible for the cost of the evaluation.
Appears in 1 contract
Samples: Product Agreement (TESARO, Inc.)
Determination of Deficiency. Upon receipt of a Deficiency Notice, Patheon will have [*****] days to advise Client by notice in writing that it disagrees with the contents of the Deficiency Notice. If Client and Patheon fail to agree within [*****] days after Patheon's notice to Client as to whether any Products identified in the Deficiency Notice deviate from the Specifications, cGMPs, cGMPs or Applicable Laws, then the parties will mutually select an independent laboratory consultant to evaluate if the Products deviate from the Specifications, cGMPs, cGMPs or Applicable Laws. This evaluation will be binding on the parties. If , and if the evaluation certifies that any Products deviate from the Specifications, cGMPs, cGMPs or Applicable Laws, Client may reject those Products in the manner contemplated in this Section 6.1 and Patheon 6.1. In this event the evaluation costs will be borne by Patheon, otherwise the Client will be responsible for the cost of the evaluationevaluation costs. If the evaluation does not so certify for in respect of any of the such Products, then Client will be deemed to have accepted delivery of such Products on the Products and Client will be responsible for [*****] after delivery (or, in the cost case of any defects not reasonably susceptible to discovery upon receipt of the evaluationProduct, on the [*****] after discovery thereof by Client, but in no event after the expiration date of the Product).
Appears in 1 contract
Samples: Manufacturing Services Agreement (Acorda Therapeutics Inc)